CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines 3-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography-Guided Percutaneous Coronary Intervention With Stent Implantation: A Systematic Review and Bayesian Network Meta-Analysis of 31 Studies and 17,882 Patients A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics Vaccination Trends in Patients With Heart Failure - Insights From Get With The Guidelines–Heart Failure Transcatheter versus Surgical Aortic Valve Replacement in Patients with Prior Cardiac Surgery in the Randomized PARTNER 2A Trial Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation Long-term results after PCI of unprotected distal left main coronary artery stenosis: the Bifurcations Bad Krozingen (BBK)-Left Main Registry

GuidelineVolume 73, Issue 24, June 2019

JOURNAL:J Am Coll Cardiol. Article Link

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

SM Grundy, NJ Stone, AL Bailey et al. Keywords: ACC/AHA Clinical Practice Guidelines; biomarkers; coronary artery calcium score; pharmacological; cardiovascular disease; cholesterol; LDL-cholesterol; diabetes mellitus; drug therapy; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; primary prevention; risk assessment; risk reduction discussion; risk treatment discussion; secondary prevention; ezetimibe; proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors

FULL TEXT PDF